Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
September 2014, Vol 5, No 7
September 2014, Vol 5, No 7
Value Propositions - September 2014
Economics & Value
,
Value Propositions
,
Value Peer-spectives
September 2014, Vol 5, No 7
Read Article
Noninvasive Imaging Technology Distinguishes Between Benign and Malignant Skin Lesions
By
Rosemary Frei, MSc
Melanoma
,
Solid Tumors
September 2014, Vol 5, No 7
Toronto, Ontario—New laser-based imaging technology differentiates malignant melanoma from other cancerous and benign skin lesions, according to a preliminary study presented at the 2014 Canadian Dermatology Association annual conference.
Read Article
Predictive Testing Holds More Value to Oncology Stakeholders than Prognostic Testing
By
Wayne Kuznar
Cancer Care
September 2014, Vol 5, No 7
Los Angeles, CA—Predictive testing offers greater value over prognostic testing to most stakeholders in cancer care, because it has a direct impact on disease treatment rather than simply predicting the course of the disease (which is, ironically, the role of prognostic testing), said S. Macey Johnson III, MBA, Vice President, Managed Care and Reimbursement, bioTheranostics, San Diego, CA, at the Fourth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Oncologists Show Low Genomic Confidence about the Use of Genetic Testing
By
Laura Morgan
Personalized Medicine
September 2014, Vol 5, No 7
Predictive multiplex genomic (or genetic) testing may revolutionize the treatment of cancer by identifying targetable mutations in cancer genes for their individual patients. Although genetic testing is commercially available, its use in clinical practice has not been fully investigated.
Read Article
In the Literature - September 2014
In the Literature
September 2014, Vol 5, No 7
Read Article
Should You Consider the Interests of Society at Large When Treating the Individual Patient?
By
Wayne Kuznar
Value in Oncology
September 2014, Vol 5, No 7
Chicago, IL—With finite healthcare resources, do physicians have a duty to serve society broadly by being responsible stewards of those shared resources, or is their obligation to the patients before them incompatible with any rationing?
Read Article
Financial Toxicity: The Elephant in the (Side Effect) Room
By
Barry D. Brooks, MD
Financial Toxicity
,
The Patient Perspective
September 2014, Vol 5, No 7
We have all had that patient—the patient who is prescribed a new targeted therapy and cannot comply with it because it is just too expensive. When asked directly about the reasoning for the noncompliance, the patient suggests that taking the treatment is just too expensive and, in fact, it is cheaper to die.
Read Article
Next-Generation Sequencing Provides Value to Multiple Stakeholders
By
Wayne Kuznar
September 2014, Vol 5, No 7
Los Angeles, CA—An understanding of the genomic drivers of cancer and linking therapy to these genetic alterations provides value to all stakeholders, including oncologists, payers, researchers, and patients, said Gary Palmer, MD, JD, MBA, MPH, Senior Vice President of Medical Affairs at Foundation Medicine.
Read Article
PD-1 Monoclonal Antibodies Usher in the Era of Immunotherapy in Oncology
By
Dana Butler
Immunotherapy
,
Personalized Medicine
September 2014, Vol 5, No 7
Oncologists’ excitement about the promise of immunotherapy is about to be tested in clinical practice, with the recent FDA approval of pembrolizumab (Kytruda; Merck), the first anti–programmed death receptor-1 (PD-1) monoclonal antibody
Read Article
Oncologists Can Become Value-Based Providers Using Evidence to Guide Patient Care
By
Wayne Kuznar
Value in Oncology
,
Value-Based Care
September 2014, Vol 5, No 7
Chicago, IL—Oncologists should become value-based providers by eliminating unnecessary tests, prescribing cheaper alternatives when therapeutic equivalents exist, and keep calling for payment reform, said Ezekiel J. Emanuel, MD, PhD, Chair, Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, at the 2014 American Society of Clinical Oncology meeting, during a session on defining value from different stakeholder perspectives.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma